https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 25 Aug 2021 11:22:54 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/jv8jj4d9v4e-management-of-car-t-related-side-effects/ Fri, 26 Feb 2021 14:08:27 +0000 http://13.40.107.223/video/jv8jj4d9v4e-management-of-car-t-related-side-effects/ Ibrahim Yakoub-Agha, MD, PhD, Lille University Hospital, Lille, France, briefly discusses the management of CAR-T related side effects, including cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Close monitoring for CRS and ICANS is required throughout the treatment course. Additionally, pre-existing neurological comorbidities may be a risk factor for the development of ICANS. Therefore, the patients should be evaluated before CAR-T therapy to rule out pre-existing neurological abnormalities. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/a9rlltqnl6s-cytopenias-post-car-t-cell-therapy/ Fri, 26 Feb 2021 14:08:26 +0000 http://13.40.107.223/video/a9rlltqnl6s-cytopenias-post-car-t-cell-therapy/ Ibrahim Yakoub-Agha, MD, PhD, Lille University Hospital, Lille, France, discusses novel insights into the pathophysiology of cytopenias post-CAR T-cell therapy. Prof. Yakoub-Agha highlights some of the mechanisms of prolonged cytopenias, such as pre-existing poor marrow reserve, observed in heavily pre-treated patients, pre-existing myelodysplastic syndromes, and changes in SDF-1. The relation between high-grade cytokine-release syndrome (CRS) and prolonged cytopenias is also debated. This interview took place during the 3rd European CAR T-cell Meeting.

]]>